Study on medical economic evaluation methods for metastatic brain tumors therapy

Tomoyuki Takura, Motohiro Hayashi, Yoshihiro Muragaki, Hiroshi Iseki, Yoshio Uetsuka

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: Treatment design for metastatic brain tumors is required to firstly care about the life and function for which the patient hopes because it is terminal care. Therefore, to discuss the value of the therapy, a viewpoint of the QOL and the socioeconomic factors other than the survival rate is important. However, examination that applies these factors to the therapy needs to be carried out more thoroughly. With this in mind, we discuss cost effectiveness of therapy for metastatic brain tumor, through a pilot study on gamma knife therapy. Materials and method: We studied 18 patients (mean age 61.6 years old) undergoing therapy for metastatic brain tumors. The health rate QOL was assessed by the profile-type measure SF-36 (Short-Form 36-Item Ver1.2) and the preference-based measure EQ-5D (EuroQoL-5D), before and six months after gamma knife therapy. Cost-utility-analysis (yen/Qaly) was carried out from quality adjusted life years (Qalys) and medical fee claims. In addition, we made a correlation analysis of the irradiation procedure and the gains attained. Results: The observation by SF-36 for six months was useful for metastatic brain tumor. As a result, the QOL indicators showed increased mental health (MH: p=0.040) and role emotional (RE: p=0.029) with significant difference. In the measurement of EQ-5D. it was added only for one month based on the significant difference (p=0.022) from the pre-therapy QOL. The utilities that were analyzed became 0.052±0.175SD (score), and Qalys were 0.135. Because the cost was 721.4±5.2SD (thousand yen), the performance of cost-utility-analysis was estimated as 5,330,000 (yen/Qaly). In addition, positive correlation (r=0.845/p=0.034) was found between the EQ-5D utility score and the tumor irradiation energy (mJ), etc. Conclusion: We established a new value over and above mere survival rate concerning metastatic brain tumor therapy. The socioeconomics and efficacy of therapy are more difficult to discuss in this disease than in other diseases. We did this by clarifying the measurement and analysis of QOL as compared with the cost factor. We found that quantitatively, the mental health rate involved in the QOL, had improved. We established that it is appropriate to cover this disease by public insurance, because cost-utility-analysis showed that it was under the threshold line. Our study also suggested that, when guessing the QOL of the prognosis, there should be grades of sensitivity according to the irradiation element involved in the therapy.

Original languageEnglish
Pages (from-to)629-637
Number of pages9
JournalNeurological Surgery
Volume38
Issue number7
Publication statusPublished - 2010 Jul
Externally publishedYes

Fingerprint

Medical Economics
Brain Neoplasms
Cost-Benefit Analysis
Therapeutics
Quality-Adjusted Life Years
Mental Health
Survival Rate
Medical Fees
Costs and Cost Analysis
Terminal Care
Insurance

Keywords

  • Cost effectiveness analysis
  • Gamma knife
  • Medical economic evaluation
  • Peripheral dose
  • Qalys

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Takura, T., Hayashi, M., Muragaki, Y., Iseki, H., & Uetsuka, Y. (2010). Study on medical economic evaluation methods for metastatic brain tumors therapy. Neurological Surgery, 38(7), 629-637.

Study on medical economic evaluation methods for metastatic brain tumors therapy. / Takura, Tomoyuki; Hayashi, Motohiro; Muragaki, Yoshihiro; Iseki, Hiroshi; Uetsuka, Yoshio.

In: Neurological Surgery, Vol. 38, No. 7, 07.2010, p. 629-637.

Research output: Contribution to journalArticle

Takura, T, Hayashi, M, Muragaki, Y, Iseki, H & Uetsuka, Y 2010, 'Study on medical economic evaluation methods for metastatic brain tumors therapy', Neurological Surgery, vol. 38, no. 7, pp. 629-637.
Takura T, Hayashi M, Muragaki Y, Iseki H, Uetsuka Y. Study on medical economic evaluation methods for metastatic brain tumors therapy. Neurological Surgery. 2010 Jul;38(7):629-637.
Takura, Tomoyuki ; Hayashi, Motohiro ; Muragaki, Yoshihiro ; Iseki, Hiroshi ; Uetsuka, Yoshio. / Study on medical economic evaluation methods for metastatic brain tumors therapy. In: Neurological Surgery. 2010 ; Vol. 38, No. 7. pp. 629-637.
@article{2fc2fe05a3fe48379eb79f526ed8fd23,
title = "Study on medical economic evaluation methods for metastatic brain tumors therapy",
abstract = "Introduction: Treatment design for metastatic brain tumors is required to firstly care about the life and function for which the patient hopes because it is terminal care. Therefore, to discuss the value of the therapy, a viewpoint of the QOL and the socioeconomic factors other than the survival rate is important. However, examination that applies these factors to the therapy needs to be carried out more thoroughly. With this in mind, we discuss cost effectiveness of therapy for metastatic brain tumor, through a pilot study on gamma knife therapy. Materials and method: We studied 18 patients (mean age 61.6 years old) undergoing therapy for metastatic brain tumors. The health rate QOL was assessed by the profile-type measure SF-36 (Short-Form 36-Item Ver1.2) and the preference-based measure EQ-5D (EuroQoL-5D), before and six months after gamma knife therapy. Cost-utility-analysis (yen/Qaly) was carried out from quality adjusted life years (Qalys) and medical fee claims. In addition, we made a correlation analysis of the irradiation procedure and the gains attained. Results: The observation by SF-36 for six months was useful for metastatic brain tumor. As a result, the QOL indicators showed increased mental health (MH: p=0.040) and role emotional (RE: p=0.029) with significant difference. In the measurement of EQ-5D. it was added only for one month based on the significant difference (p=0.022) from the pre-therapy QOL. The utilities that were analyzed became 0.052±0.175SD (score), and Qalys were 0.135. Because the cost was 721.4±5.2SD (thousand yen), the performance of cost-utility-analysis was estimated as 5,330,000 (yen/Qaly). In addition, positive correlation (r=0.845/p=0.034) was found between the EQ-5D utility score and the tumor irradiation energy (mJ), etc. Conclusion: We established a new value over and above mere survival rate concerning metastatic brain tumor therapy. The socioeconomics and efficacy of therapy are more difficult to discuss in this disease than in other diseases. We did this by clarifying the measurement and analysis of QOL as compared with the cost factor. We found that quantitatively, the mental health rate involved in the QOL, had improved. We established that it is appropriate to cover this disease by public insurance, because cost-utility-analysis showed that it was under the threshold line. Our study also suggested that, when guessing the QOL of the prognosis, there should be grades of sensitivity according to the irradiation element involved in the therapy.",
keywords = "Cost effectiveness analysis, Gamma knife, Medical economic evaluation, Peripheral dose, Qalys",
author = "Tomoyuki Takura and Motohiro Hayashi and Yoshihiro Muragaki and Hiroshi Iseki and Yoshio Uetsuka",
year = "2010",
month = "7",
language = "English",
volume = "38",
pages = "629--637",
journal = "Neurological Surgery",
issn = "0301-2603",
publisher = "Igaku-Shoin Ltd",
number = "7",

}

TY - JOUR

T1 - Study on medical economic evaluation methods for metastatic brain tumors therapy

AU - Takura, Tomoyuki

AU - Hayashi, Motohiro

AU - Muragaki, Yoshihiro

AU - Iseki, Hiroshi

AU - Uetsuka, Yoshio

PY - 2010/7

Y1 - 2010/7

N2 - Introduction: Treatment design for metastatic brain tumors is required to firstly care about the life and function for which the patient hopes because it is terminal care. Therefore, to discuss the value of the therapy, a viewpoint of the QOL and the socioeconomic factors other than the survival rate is important. However, examination that applies these factors to the therapy needs to be carried out more thoroughly. With this in mind, we discuss cost effectiveness of therapy for metastatic brain tumor, through a pilot study on gamma knife therapy. Materials and method: We studied 18 patients (mean age 61.6 years old) undergoing therapy for metastatic brain tumors. The health rate QOL was assessed by the profile-type measure SF-36 (Short-Form 36-Item Ver1.2) and the preference-based measure EQ-5D (EuroQoL-5D), before and six months after gamma knife therapy. Cost-utility-analysis (yen/Qaly) was carried out from quality adjusted life years (Qalys) and medical fee claims. In addition, we made a correlation analysis of the irradiation procedure and the gains attained. Results: The observation by SF-36 for six months was useful for metastatic brain tumor. As a result, the QOL indicators showed increased mental health (MH: p=0.040) and role emotional (RE: p=0.029) with significant difference. In the measurement of EQ-5D. it was added only for one month based on the significant difference (p=0.022) from the pre-therapy QOL. The utilities that were analyzed became 0.052±0.175SD (score), and Qalys were 0.135. Because the cost was 721.4±5.2SD (thousand yen), the performance of cost-utility-analysis was estimated as 5,330,000 (yen/Qaly). In addition, positive correlation (r=0.845/p=0.034) was found between the EQ-5D utility score and the tumor irradiation energy (mJ), etc. Conclusion: We established a new value over and above mere survival rate concerning metastatic brain tumor therapy. The socioeconomics and efficacy of therapy are more difficult to discuss in this disease than in other diseases. We did this by clarifying the measurement and analysis of QOL as compared with the cost factor. We found that quantitatively, the mental health rate involved in the QOL, had improved. We established that it is appropriate to cover this disease by public insurance, because cost-utility-analysis showed that it was under the threshold line. Our study also suggested that, when guessing the QOL of the prognosis, there should be grades of sensitivity according to the irradiation element involved in the therapy.

AB - Introduction: Treatment design for metastatic brain tumors is required to firstly care about the life and function for which the patient hopes because it is terminal care. Therefore, to discuss the value of the therapy, a viewpoint of the QOL and the socioeconomic factors other than the survival rate is important. However, examination that applies these factors to the therapy needs to be carried out more thoroughly. With this in mind, we discuss cost effectiveness of therapy for metastatic brain tumor, through a pilot study on gamma knife therapy. Materials and method: We studied 18 patients (mean age 61.6 years old) undergoing therapy for metastatic brain tumors. The health rate QOL was assessed by the profile-type measure SF-36 (Short-Form 36-Item Ver1.2) and the preference-based measure EQ-5D (EuroQoL-5D), before and six months after gamma knife therapy. Cost-utility-analysis (yen/Qaly) was carried out from quality adjusted life years (Qalys) and medical fee claims. In addition, we made a correlation analysis of the irradiation procedure and the gains attained. Results: The observation by SF-36 for six months was useful for metastatic brain tumor. As a result, the QOL indicators showed increased mental health (MH: p=0.040) and role emotional (RE: p=0.029) with significant difference. In the measurement of EQ-5D. it was added only for one month based on the significant difference (p=0.022) from the pre-therapy QOL. The utilities that were analyzed became 0.052±0.175SD (score), and Qalys were 0.135. Because the cost was 721.4±5.2SD (thousand yen), the performance of cost-utility-analysis was estimated as 5,330,000 (yen/Qaly). In addition, positive correlation (r=0.845/p=0.034) was found between the EQ-5D utility score and the tumor irradiation energy (mJ), etc. Conclusion: We established a new value over and above mere survival rate concerning metastatic brain tumor therapy. The socioeconomics and efficacy of therapy are more difficult to discuss in this disease than in other diseases. We did this by clarifying the measurement and analysis of QOL as compared with the cost factor. We found that quantitatively, the mental health rate involved in the QOL, had improved. We established that it is appropriate to cover this disease by public insurance, because cost-utility-analysis showed that it was under the threshold line. Our study also suggested that, when guessing the QOL of the prognosis, there should be grades of sensitivity according to the irradiation element involved in the therapy.

KW - Cost effectiveness analysis

KW - Gamma knife

KW - Medical economic evaluation

KW - Peripheral dose

KW - Qalys

UR - http://www.scopus.com/inward/record.url?scp=77954646203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954646203&partnerID=8YFLogxK

M3 - Article

VL - 38

SP - 629

EP - 637

JO - Neurological Surgery

JF - Neurological Surgery

SN - 0301-2603

IS - 7

ER -